Products with Anti-inflammatory bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN6222 | Ergosterol peroxide glucoside |
| 1. Ergosterol peroxide exhibits inhibitory effects on human breast adenocarcinoma MCF-7 cells, it inhibits the growth of MCF-7 cells by inducing cell apoptosis. 2. Ergosterol peroxide exhibits hACAT-1 and Lp-PLA2 inhibitory effects, with inhibitory values of 51.6 +/- 0.9 and 51.7 +/- 1.2%, at a treatment concentration of 0.23 mM; suggests that it could as an anti-atherosclerosis agent. 3. Ergosterol peroxide shows very strong anticomplementary activity on the classical pathway, the IC(50) values being 5.0 muM. 4. Ergosterol peroxide can suppress inflammatory responses in RAW264.7 macrophages and growth of HT29 colon adenocarcinoma cells, it appears to suppress cell growth and STAT1 mediated inflammatory responses by altering the redox state in HT29 cells. 5. Ergosterol peroxide has anti-melanogenic activity. 6. Ergosterol peroxide has amoebicidal activity (IC50 =4.23nM), it produces a strong cytotoxic effect against amoebic growth. 7. Ergosterol peroxide has osteoclastogenesis inhibitory effect, it shows an inhibitory effect in a dose-dependent manner and an inhibition rate of up to 62% with low cytotoxicity, even at a concentration as low as 1.0 microg/mL. 8. Ergosterol peroxide has antibacterial activity against Mycobacterium tuberculosis and has antiviral action. 9. Ergosterol peroxide has anti-oxdiant activity. | |
| BCN6231 | Asperuloside |
| Asperuloside exerts its anti-inflammatory effect in correlation with inhibition of a pro-inflammatory mediator through suppressing nuclear factor kappa-B (NF-κB) nuclear translocation and MAPK phosphorylation in a dose-dependent manner. Chronic administration of Asperuloside stimulates anti-obesity and anti-metabolic syndrome activity in HFD-fed rats across several organs, similar to Eucommia leaf extract (ELE) administration. | |
| BCN6250 | Hispidulin |
| Hispidulin has anti-oxidative, anti-inflammatory, anti-cancer, antiepileptic, neuroprotective, anti-osteoporotic and bone resorption attenuating effects, it targets the VEGF receptor 2-mediated PI3K/Akt/mTOR signaling pathway in endothelial cells, leading to the suppression of pancreatic tumor growth and angiogenesis. Hispidulin can ameliorate high glucose-mediated endothelial dysfunction via inhibiting PKCβII-associated NLRP3 inflammasome activation and NF-κB signaling, it has potential application in the prevention and treatment of diabetic vascular complications. Hispidulin can inhibit platelet aggregation by elevating cAMP levels by a mechanism different from that of theophylline or PGE1. | |
| BCN6261 | Yunaconitine |
| 1. Yunaconitine,extracted from several plants of Aconitum, has anti-inflammatory and analgesic actions. 2. Yunaconitine can increase serum total complement as well as the phag-ocytic activity of reticuloendothelial system in mice, these effects are considered to be beneficial in the clearance of pathogenic antigens, and may be the immunopharmacological basis of antiinflammatory actions of yunaconitine. | |
| BCN6265 | Sinomenine |
| Sinomenine shows neuroprotective, anti- rheumatoid arthritis, anti-inflammatory and immunosuppressive effects, it can attenuate 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice and the therapeutic mechanism may be related to the reduction of up-regulated colonic TNF-alpha and IFN-gamma production caused by TNBS. Sinomenine also provides a novel therapy to treat ICH induced brain injury. Sinomenine can prevent galactosamine (GalN)/lipopolysaccharide (LPS) -treated hepatic failure by suppressing TNF production and/or reactive oxygen generation. | |
